Laurion Capital Management LP Allakos Inc. Transaction History

Laurion Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$79.58 - $152.45 $596,850 - $1.14 Million	-7,500 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$66.43 - $90.99 $237,221 - $324,925	-3,571 Reduced 32.26%	7,500 $611,000
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $487,566 - $893,318	11,071 New	11,071 $796,000
Q4 2018 Feb 14, 2019	SELL	$31.59 - $62.65 $3.16 Million - $6.27 Million	-100,000 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$31.25 - $47.64 $3.13 Million - $4.76 Million	100,000 New	100,000 $4.5 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.